Molecular Genetics of Type 2 von Willebrand Disease

被引:0
|
作者
Edith Fressinaud
Claudine Mazurier
Dominique Meyer
机构
[1] INSERM U.143,
[2] Le Kremlin-Bicětre,undefined
[3] LFB,undefined
[4] INSERM U.143,undefined
[5] 84,undefined
[6] rue du Général leclerc,undefined
来源
关键词
von Willebrand disease; Type 2 von Willebrand disease; von Willebrand factor genetics;
D O I
暂无
中图分类号
学科分类号
摘要
Type 2 von Willebrand disease (VWD) is characterized by a wide heterogeneity of functional and structural defects. These abnormalities cause either defective von Willebrand factor (VWF)-dependent platelet function in subtypes 2A, 2B, and 2M or defective VWF-factor VIII (FVIII) binding in subtype 2N. The diagnoses of types 2A, 2B, and 2M VWD may be guided by the observation of disproportionately low levels of ristocetin cofactor activity or collagen-binding capacity relative to VWF antigen. The abnormal platelet-dependent function is often associated with the absence of high molecular weight (HMW) multimers (type 2A, type 2B), but the HMW multimers may also be present (type 2M, some type 2B), and supranormal multimers may exist (“Vicenza” variant). The observation of a low FVIII-to-VWF:Ag ratio is a hallmark of type 2N VWD, in which the FVIII levels depend on the severity of the FVIII-binding defect. Today, the identification of mutations in particular domains of the pre-pro-VWF is helpful in classifying these variants and providing further insight into the structure-function relationship and the biosynthesis of VWF. Thus, mutations in the D2 domain, involved in the multi-merization process, are found in patients with type 2A, formerly named IIC VWD. Mutations located in the D’ domain or in the N terminus of the D3 domain define type 2N VWD. Mutations in the D3 domain characterize Vicenza and IIE patients. Mutations in the A1 domain may modify the binding of VWF multimers to platelets, either increasing (type 2B) or decreasing (type 2M, 2A/2M) the affinity of VWF for platelets. In type 2A VWD, molecular abnormalities identified in the A2 domain, which contains a specific proteolytic site, are associated with alterations in folding, impairing VWF secretion or increasing its susceptibility to proteolysis. Finally, a mutation localized in the carboxy-terminus CK domain, which is crucial for the dimerization of the VWF subunit, has been identified in a rare subtype 2A, formerly named IID.
引用
收藏
页码:9 / 18
页数:9
相关论文
共 50 条
  • [41] Genetics of type 1 von Willebrand disease (vol 14, pg 444, 2007)
    Goodeve, Anne
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (02) : 154 - 154
  • [42] von Willebrand factor pseuclogene conversion as the cause of type 2M and type 3 von Willebrand disease
    Enayat, M. S.
    Guilliatt, A. M.
    Chalmers, E. A.
    Wilde, J. T.
    Williams, M. D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 77 - 77
  • [43] Type 1 von Willebrand disease
    Peake, I.
    Goodeve, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 : 7 - 11
  • [44] Novel mutation in the von Willebrand Factor gene of type 2 von Willebrand Disease seen in Taiwan
    Shen, M. C.
    Lin, B. D.
    Lin, H. Y.
    Tsai, W.
    Lin, J. S.
    Kuo, S. F.
    Hong, M. H.
    Wang, Y. C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1146 - 1146
  • [45] Molecular assessment of FVIII binding site in von Willebrand factor gene in suspects patients of von Willebrand disease type 2N
    Damian, G. B.
    Santos, A.
    Di Migueli, Oliveira C.
    Siqueira, L.
    Prezoti, A.
    Di Paula, E.
    Bizzacchi, J.
    Ozelo, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 840 - 840
  • [46] Interaction of factor VIII and von Willebrand factor and the identification of type 2 N von Willebrand disease
    Favaloro, Emmanuel J.
    THROMBOSIS RESEARCH, 2011, 127 (01) : 2 - 3
  • [47] VON WILLEBRAND DISEASE TYPE 2A DUE TO A RARE VON WILLEBRAND FACTOR MISSENSE MUTATION
    Van Helmond, Jennifer
    Chopra, Aarushi
    Hernandez, Jessa
    Mysore, Sukrita
    Ahmed, Rafat
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S73 - S73
  • [48] Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques
    Nesbitt, IM
    Goodeve, AC
    Guilliatt, AM
    Makris, M
    Preston, FE
    Peake, IR
    THROMBOSIS AND HAEMOSTASIS, 1996, 75 (06) : 959 - 964
  • [49] Von Willebrand factor inhibitors developed in type 3 von Willebrand disease
    Megdiche, F.
    Kassar, O.
    Hdiji, S.
    Mbarek, L.
    Charfi, M.
    Elloumi, M.
    Kallel, C.
    HAEMOPHILIA, 2019, 25 : 87 - 87
  • [50] Reduced von Willebrand factor survival in type Vicenza von Willebrand disease
    Casonato, A
    Pontara, E
    Sartorello, F
    Cattini, MG
    Sartori, MT
    Padrini, R
    Girolami, A
    BLOOD, 2002, 99 (01) : 180 - 184